Computer-Aided Drug Design in Anticancer Drugs
DOI:
https://doi.org/10.61173/j5m79556Keywords:
Anticancer Drugs, Cancer poses, molecular, bendamustine, Ligand-based drug designAbstract
The fight against cancer is a significant global health issue, and creating effective anticancer medications is crucial to addressing this challenge. Traditional methods of developing these drugs are time-consuming and require substantial financial investment. However, computer-aided drug design technology can reduce the time and cost associated with research and development. This paper summarizes various studies that have utilized computer-aided drug design technology to create anticancer drugs. It explores the application of this technology in cancer research and serves as a reference for future development of anticancer medications.
References
[1] Acharya, C., Coop, A., E. Polli, J., & D. MacKerell, A. (2011). Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally Sampled Pharmacophore Approach. Current Computer Aided-Drug Design, 7(1), 10–22.
[2] Ambure, P., & Roy, K. (2017). CADD Modeling of Multi- Target Drugs Against Alzheimer’s Disease. Current Drug Targets, 18(5), 522–533.
[3] Baig, M. H., Ahmad, K., Rabbani, G., Danishuddin, M., & Choi, I. (2018). Computer-Aided Drug Design and its Application to Developing Potential Drugs for Neurodegenerative Disorders. Current Neuropharmacology, 16(6), 740–748.
[4] Cheng, H., Orr, S. T. M., Bailey, S., Brooun, A., Chen, P., Deal, J. G., Deng, Y. L., Edwards, M. P., Gallego, G. M., Grodsky, N., Huang, B., Jalaie, M., Kaiser, S., Kania, R. S., Kephart, S. E., Lafontaine, J., Ornelas, M. A., Pairish, M., Planken, S., … Kath, J. C. (2021). Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195). Journal of Medicinal Chemistry, 64(1), 644–661.
[5] Clement, O. O., Freeman, C. M., Hartmann, R. W., Handratta, V. D., Vasaitis, T. S., Brodie, A. M. H., & Njar, V. C. O. (2003). Three-Dimensional Pharmacophore Modeling of Human CYP17 Inhibitors. Potential Agents for Prostate Cancer Therapy. Journal of Medicinal Chemistry, 46(12), 2345–2351.
[6] Ganji, M., Bakhshi, S., Shoari, A., & Ahangari Cohan, R.
[2023] . Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer. Journal of Translational Medicine, 21(1), 111.
[7] Huang, H.-J., Kraevaya, O. A., Voronov, I. I., Troshin, P. A., & Hsu, S. (2020). Fullerene Derivatives as Lung Cancer Cell Inhibitors: Investigating Potential Descriptors Using QSAR Approaches. International Journal of Nanomedicine, Volume 15, 2485–2499.
[8] Kapetanovic, I. M. (2008). Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. Chemico-Biological Interactions, 171(2), 165–176.
[9] Llorach-Pares, L., Nonell-Canals, A., Avila, C., & Sanchez- Martinez, M. (2022). Computer-Aided Drug Design (CADD) to De-Orphanize Marine Molecules: Finding Potential Therapeutic Agents for Neurodegenerative and Cardiovascular Diseases. Marine Drugs, 20(1), 53.
[10] McInnes, C. (2007). Virtual screening strategies in drug discovery. Current Opinion in Chemical Biology, 11(5), 494–
[502] https://doi.org/10.1016/j.cbpa.2007.08.033
[11] Russo Spena, C., De Stefano, L., Poli, G., Granchi, C., El Boustani, M., Ecca, F., Grassi, G., Grassi, M., Canzonieri, V., Giordano, A., Tuccinardi, T., Caligiuri, I., & Rizzolio, F. (2019). Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects. Journal of Cellular Physiology, 234(9), 15708–15716.
[12] Sharma, T., Saralamma, V. V. G., Lee, D. C., Imran, M. A., Choi, J., Baig, M. H., & Dong, J.-J. (2022). Combining structure-based pharmacophore modeling and machine learning for the identification of novel BTK inhibitors. International Journal of Biological Macromolecules, 222, 239–250.
[13] Song, Y.-Q., Wu, C., Wu, K.-J., Han, Q.-B., Miao, X.-M., Ma, D.-L., & Leung, C.-H. (2021). Ubiquitination Regulators Discovered by Virtual Screening for the Treatment of Cancer. Frontiers in Cell and Developmental Biology, 9, 665646.
[14] Tamanini, E., Buck, I. M., Chessari, G., Chiarparin, E., Day, J. E. H., Frederickson, M., Griffiths-Jones, C. M., Hearn, K., Heightman, T. D., Iqbal, A., Johnson, C. N., Lewis, E. J., Martins, V., Peakman, T., Reader, M., Rich, S. J., Ward, G. A., Williams, P. A., & Wilsher, N. E. (2017). Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP). Journal of Medicinal Chemistry, 60(11), 4611–4625.
[15] Van Montfort, R. L. M., & Workman, P. (2017). Structurebased drug design: Aiming for a perfect fit. Essays in Biochemistry, 61(5), 431–437. https://doi.org/10.1042/ EBC20170052
[16] WHO. (2023). The World Health Organization. www.who.int
[17] Yang, S.-Y. (2010). Pharmacophore modeling and applications in drug discovery: Challenges and recent advances. Drug Discovery Today, 15(11), 444–450.
[18] Zhang, N.-N., Ban, Y.-J., Wang, Y.-J., He, S.-Y., Qi, P.-P., Bi, T., Ma, Y.-F., Dong, Y.-X., Guo, B., Weng, J., Li, H.-L., Tang, L., & Zhang, J.-Q. (2023). Virtual screening of novel mTOR inhibitors for the potential treatment of human colorectal cancer. Bioorganic Chemistry, 140, 106781.
[19] Zhou, Y., Chen, Y., Huang, X., Tan, Y., Hu, R., Li, C., & Niu, M. (2021). A Supramolecular Nanomedicine Based on Bendamustine and MDM2‐Targeted D‐peptide Inhibitor for Breast Cancer Therapy. Advanced Healthcare Materials, 10(21), 2100980.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
